Pacifico Yokohama, Japan      October 9 (Wed.) – 11 (Fri.), 2019

To Pre-register for the seminars, please complete the visitor registration first.
*If you already completed above, you can proceed your seminar registration from your visitor account.
✔ Register Now → Account Login

Organizer

Oct.9(Wed.)      10  :  00  ~  11  :  30

F203-206
【K-1】 Keynote Lecture
Pre-Registration required Simultaneous interpretation

Keynote Lecture 

Bioeconomy Strategy 2019 for Japan

Dr. Hiroto Izumi

Special Advisor to the Prime Minister
Cabinet Secretariat

AI for BioMedical Sciences

Mr. Hiroaki Kitano

President & CEO
Sony Computer Science Laboratories Inc.

In Japanese

Prof. Paul Workman

Chief Executive and President,
The Institute of Cancer Research

Organizer

Oct.9(Wed.)      12  :  30  ~  13  :  30

F203
【O-1】 VIP Vision for Innovation
Admission Fee required Pre-Registration required Simultaneous interpretation

VIP Vision for Innovation 

Coordinator

Dr. Hitoshi Kuboniwa

Chairman of the Steering Committee, Japan Bioindustry Assocition(JBA)
Japan Bioindustory Association

Prof. Maggie Dallman

Vice-President (International),
Imperial College London

New Priorities at PMDA -Pursuing 4 Firsts-

Dr. Yasuhiro Fujiwara

Chief Executive
Pharmaceuticals and Medical Devices Agency

Organizer

Oct.9(Wed.)      14  :  00  ~  15  :  30

Main Stage
【M-1】 Life Innovation Forum - Japan's New Strategy on Bio-business -
Pre-Registration not required Simultaneous interpretation

Life Innovation Forum - Japan's New Strategy on Bio-business - (tentative) 

In accord with keynote lecture regarding the strategy on bio-business 2019, key persons within goverment and industry discuss about implementation of the strategy. Session will be held at exhibition hall and active discussion with floor will be expected.

Coordinator

Dr. Hitoshi Kuboniwa

Chairman of the Steering Committee, Japan Bioindustry Assocition(JBA)
Japan Bioindustory Association


Mr. Esaki Yoshihide

Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

In Japanese

Mr. Nagayama Osamu

Japan Bioindustry Association

In Japanese

Mr. Aramaki Koichiro


Driving Force to Create the Industry of Regenerative Medicine.

Dr. KEN-ICHIRO HATA

Representative Director,Chairman
Forum for Innovative Regenerative Medicine

In Japanese

Luncheon

Oct.9(Wed.)      11  :  45  ~  12  :  45

F201
【L-1】 Bayer Yakuhin, Ltd.
Pre-Registration required Simultaneous interpretation

Open Innovation Strategy at Bayer 

Coordinator

Alliance Manager
Open Innovation Center Japan
Bayer Yakuhin, Ltd.

Co-creation of Innovation at Bayer

Dr. Ziegelbauer Karl

Head of Open Innovation & Digital Technologies
Bayer AG

Partnership and Innovation at Bayer in Japan

Open Innovation Center Japan
Bayer Yakuhin, Ltd.

In Japanese

Oct.9(Wed.)      13  :  15  ~  14  :  15

F201
【S-1】 NOSTER Bio-Institute, Nitto Pharma
Pre-Registration required Simultaneous interpretation

New medical innovation with gut microbes 

The functions of gut microbiota are considered to be important in the creation of new drug-discovery category and extending the future healthy life. They are mainly derived from the gut microbial components themselves and gut microbial metabolites. In this session, we will introduce the latest findings, the effect of gut microorganisms on cardiovascular diseases and the inflammatory suppression effect in intestinal tract by gut microbial lipid metabolites, and discuss future developments of pharmaceutical seeds based on the above-mentioned results.

1. It found that two species, Bacteroides vulgatus and Bacteroides dorei, were significantly decreased in the patients with Coronary Artery Disease. When two species were orally administered to the mice with arteriosclerosis, it significantly suppressed the formation of arteriosclerosis and decreased the activity of LPS (liposaccharides), the inflammatory substances. In addition, the low ratio of two species was found in the feces of the patient with high LPS activity and vice versa. The results indicated the relationship with anti-inflammatory activity. Thus, we develop two species as drug discovery seeds for the suppression of arteriosclerosis
2. It becomes well-known that intestinal inflammation relates various diseases. HYA, the gut microbial lipid metabolites, is expected to be a new therapeutic by suppression of inflammatory.

Coordinator

Prof. Jun Ogawa

Professor
Division of Applied Life Sciences,
Graduate School of Agriculture, Kyoto University

New trends of gut microbial function development

Prof. Jun Ogawa

Professor
Division of Applied Life Science,
Graduate School of Agriculture Kyoto University

In Japanese

Prevention of atherosclerosis using gut-microbiota drugs

Dr. Tomoya Ysmashita

Associate Professor
Cardiovascular Division
Kobe University Hospital

In Japanese

Anti-inflammatory effect of gut microbial lipid metabolite, 10-hydroxy-cis-12-octadecenoic acid

Dr. Yasunori Yonejima

Research Manager
Microbiome group, NOSTER Bio-institute
Nitto Pharmaceutical Industries, LTD.

In Japanese

Organizer

Oct.9(Wed.)      14  :  15  ~  15  :  45

F204
【O-2】 Next Generation Antibody Drugs
Admission Fee required Pre-Registration required Simultaneous interpretation

Next Generation Antibody Drugs 

Coordinator


Drug Discovery Driven by Antibody Engineering Technologies

Dr. Igawa Tomoyuki

Global Biologics Leader , CEO and Research Head
Chugai Pharmabody Research Pte. Ltd.

In Japanese

Towards the decoding of the Immune Repertoire

Dr. Yamashita Kazuo

Recent advances of camelid-derived single domain VHH antibody

Dr. Yoshihisa Hagihara

Deputy Director
Biomedical Research Institute
National Institute of Advanced Industrial Science and Technology (AIST)

In Japanese

Oct.9(Wed.)      14  :  30  ~  15  :  30

F201
【S-6】 Janssen Pharmaceutical K.K.
Pre-Registration required Simultaneous interpretation

Johnson&Johnson and Janssen innovation strategy in global and Japan 

Presentation of Johnson&Johnson / Janssen's focus therapeutic area and capability for future potential partners (academia, biotech, and Pharma).

Ms. Cindy Warren

VP,
Janssen Business Development

Dr. Kenji Nonaka

VP,
Head of Janssen Japan R&D

Dr. Andrew Wong

Head,
Johnson and Johnson INNOVATION – Asia Pacific

Mr. Satoshi Daigo

Associate Director,
Janssen Business Development (Japan)


Organizer

Oct.9(Wed.)      15  :  30  ~  16  :  45

F203
【O-3】 Ito Review 2.0:Biomedical Edition" - Issues and Perspectives - (tentative)
Admission Fee required Pre-Registration required Simultaneous interpretation

Ito Review 2.0:Biomedical Edition"
- Issues and Perspectives - (tentative)
 

Coordinator

Prof. Ito Kunio

Professor
Graduate school of Commerce and Management
Hitotsubashi University

Opportunity for developing new benchmark index to link Japanese Biotech companies and institutional investors.

Mr. Yoshiyuki Makino

Managing Director
Head of Japan Office
S&P Dow Jones Indices

In Japanese

Mr. Iwaya Shohei

Asset Management One Co., Ltd.

In Japanese


Mr. Hironoshin Nomura

Senior Analyst
Equity Research
Mizuho Securities Co.,Ltd.

In Japanese

Mr. Tanaka Tetsuya

Bio-Industry Division Director
Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

In Japanese

Oct.9(Wed.)      16  :  00  ~  17  :  00

F204
【S-8】 Twist Bioscience
Pre-Registration required

Twist Bioscience 

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.

Synthetic DNA Technologies Enable Antibody Discovery and Optimization

Dr. Aaron Sato

Chief Scientific Officer
Twist Biopharma
Twist Bioscience

Precision Library Generation Fueled By Twist Bioscience Silicon-Based DNA Synthesis Platform

Mr. Steven Thomas

Biopharma Application Specialist
Twist Bioscience
Twist Bioscience

Oct.9(Wed.)      16  :  00  ~  17  :  00

F201
【S-7】 Chugai Pharmaceutical Co., Ltd.
Pre-Registration required Simultaneous interpretation

Progress in personalized healthcare in oncology, and Chugai’s strategy 

Coordinator

Dr. Yasushi Ito

Executive Vice President
Chugai Pharmaceutical Co., Ltd.

Chugai Oncology Strategy –Focusing on Personalized Healthcare (PHC)

Ms. Megumi Uzu

Department Manager
Oncology Lifecycle Management Department, Project & Lifecycle Management Unit
Chugai Pharmaceutical Co., Ltd.

In Japanese

New platforms for personalized healthcare in oncology

Mr. Josh Lauer

Global Head of Personalized Healthcare Market Development
F. Hoffmann-La Roche Ltd.

Oct.10(Thu.)      10  :  00  ~  11  :  00

F202
【S-10】 Boehringer Ingelheim Japan, Inc.
Pre-Registration required

Translating Japanese research excellence into new medicines for patients in need: Working together with Boehringer Ingelheim. 

Boehringer Ingelheim (BI) was established as a family-owned company in 1885. BI is focusing on developing innovative new treatment approaches providing outstanding value for patients. To achieve this, the company is increasing its commitment to external innovation, and is working with partners from academia and industry wordwide. A growing network of collaborations across the value chain reflects the company's focus on emerging science that could open new avenues leading to the breakthrough medications of the future. Today, we would like to connect with more Japanese innovators who want to work together for better Health with BI.

The Ecosystem for innovative drug creation with Boehringer Ingelheim

Dr. Ioannis Sapountzis

Boehringer Ingelheim

Partnering experiences in Japan and Proposal/Messages to Japanese Innovators

Dr. Henri Doods

Boehringer Ingelheim

Lessons from Boehringer Academy/Innovation Prize

Dr. Yusaku Katada

CEO
Restore Vision Co., Ltd.

In Japanese

Oct.10(Thu.)      10  :  00  ~  11  :  00

F203
【S-11】 Keio University Tonomachi Town - Campus
Pre-Registration required

Bio-venture Ecosystem in the age of Open Innovation2.0 

Coordinator

AccuRna Inc.

Bio-venture Ecosystem in the age of Open Innovation2.0

Mr. Tomohiro Anzai

Fast Track Initiative, Inc.

In Japanese

Nanomedicine innovation accelerate with a venture:From diagnosis to drug discovery.

Mr. Takanori Ichiki

iXstream, Inc.

In Japanese

Utilization of AI and cloud in Bio and Drug discovery informatics

Mr. Yutaka Akiyama

Ahead Biocomputing, Co. Ltd.

In Japanese

Oct.10(Thu.)      10  :  00  ~  11  :  00

F204
【S-12】 Japan Agency for Medical Research and Development
Pre-Registration required

Development of Advanced Medical Care by Glycotechnology 

Coordinator

Prof. Michiie Sakamoto

professor
department of pathology
Keio University School of Medicine

From sugar to therapy

Prof. Tatsuro Irimura

professor
Division of Glycobiologics, Intractable Disease Research Center
Juntendo University Graduate School of Medicine

In Japanese

Glyco-target discovery: our technological impact and application strategy

Dr. Atsushi Kuno

Chief Senior Researcher
Glycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology

In Japanese

Development of molecular-targeted antibodies with glycopeptides by chemoenzymatic synthesis

Dr. Yasunori Chiba

Chief Senior Researcher
Glycoscience and Glycotechnology Research Group, Biotechnology Research Institute for Drug Discovery Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology

In Japanese

Oct.10(Thu.)      10  :  00  ~  11  :  30

F201
【S-9】 Japan Pharmaceutical Manufacturers Association
Pre-Registration required Simultaneous interpretation

The growing importance of PPP and precompetitive research collaboration in drug discovery 

In the pharmaceutical industry open innovation focusing on competitive research areas is the mainstream. However, PPP and precompetitive research collaboration where multiple pharmaceutical companies team up together to address mutual challenges in drug discovery have become more important than before. One of the reasons behind this trend is that the start point of drug discovery has changed from a hypothetical drug target to a disease-relevant drug target found by better understanding of disease mechanisms. PPP and precompetitive research collaboration are effective and practical mechanisms by which researchers can advance their research using valuable research materials including patient sample and their medical information. There is no doubt that they will be even more important in the near future when precision medicine and personalized medicine will be widely accepted by the society.

Coordinator

Dr. Damrongchai Nares

CEO
TCELS(Thailand Center of Excellence for Life Sciences)

Dr. Hasuoka Atsushi

Japan Pharmaceutical Manufacturers Association

PPP in Japan - Government's Perspective -

Okubo Takayuki

Deputy Director
Research and Development Division, Health Policy Bureau
MHLW

Public Private Partnerships: Emerging Trends for Greater Impact

Otani Akiko

Takeda Pharmaceutical Company Limited

(Tentative) GHIT Fund : A Public-Private Partnership

Dr.

Senior Director
Global Health Innovative Technology Fund (GHIT Fund)

Public Private Partnerships: Yesterday, Today and Tomorrow

Saikatendu Kumar Singh

Takeda Phamaceutical Company Limited

Organizer

Oct.10(Thu.)      11  :  30  ~  13  :  00

F202
【O-6】 Cancer Genome Medicine
Admission Fee required Pre-Registration required Simultaneous interpretation

Cancer Genome Medicine  

On June , this year, cancer genome medicine started in operation in Japan using cancer gene panel such as NCC Oncopanel and FoundationOne. Our national health insurance system reimburse genomic medicine including cancer gene panel and related medical practice only for 11 core hospitals and associated more than 100 hospitals, covering 1% of new cancer patients in Japan. We will clarify the current status and obstacles of japanese cancer genome medicine.

Coordinator

Mr. Mitsuru Miyata

CEO
Miyata Institute of Technologies

Cancer Gene Profiling test promotes Cancer Precision Medicine

Dr. hiroshi nishihara

Professor
Genomics Unit, Keio Cancer Center 
Keio University School of Medicine

In Japanese


Dr. Nobuya Ishii

Luncheon

Oct.10(Thu.)      12  :  00  ~  13  :  00

F201
【L-3】 TAKARA BIO INC.
Pre-Registration required

Development of novel engineered T cell therapies 

Prof. Hiroshi Shiku

Professor
Mie University Graduate School of Medicine

In Japanese

Oct.10(Thu.)      13  :  30  ~  14  :  30

F204
【S-25】 Eli Lilly and Company
Pre-Registration required

Lilly's external innovation ecosystem 

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. Eli Lilly and Company is committed to leveraging the world's science and building partnerships to deliver innovative medicines for the benefit of patients. At Lilly, we recognize the important role that your work plays in helping us generate innovation and achieving our common goal: improving the lives of individual patients around the world. In collaboration with our partners, we look for opportunities to help bring important medicines to the patients who need them. https://www.lilly.com/partners. In this seminar, Lilly introduces our current External Innovation Ecosystem, esp. for emerging technology and innovation.

Lilly's external innovation ecosystem

Dr. Gurkeerat Singh

Vice President
Emerging Technology and Innovation, Japan and Asia
Eli Lilly and Company

Oct.10(Thu.)      13  :  30  ~  16  :  30

F202
【S-15】 Japan Agency for Medical Research and Development
Pre-Registration required

The Second Success Story (Drug Discovery/Medical Technology) of Medical Research and Development Programs Focused on Technology Transfer: Acceleration Transformative Research for Medical Innovation (ACT-M/MS) 

Coordinator

Dr. Tsutomu Chiba

President, Kansai Electric Power Hospital; Emeritus Professor, Kyoto University; Visiting Professor, Kobe University; Chair, Committee of Intractable Disease

Dr. Seiichi Tanida

Adviser
Industry-Academia-Government Collaboration, Business Division Kyoto Lifetech Innovation Support Center
Advanced Science, Technology & Management, Research Institute of KYOTO

Dr. Kazuhiko Yamamoto

Deputy Director
RIKEN Center for Integrative Medical Sciences

Development study of TLR7 inhibitors aiming at the development of therapeutic agents for systemic lupus erythematosus

Prof. Nagai Yoshinori

Professor
Department of Pharmaceutical Engineering, Faculty of Engineering
Toyama Prefectual University

In Japanese

Development of a method by which cytotoxic T lymphocytes can be mass-produced from iPS cells for the use of allogeneic transfusion

Prof. Hiroshi Kawamoto

Professor
Institute for Frontier Life and Medical Sciences
Kyoto University

In Japanese

Development of useful biomarkers for prevention and treatment of allergy and their diagnostic devices

Prof. Hiroshi Kido

Designated Professor
Institute for Enzyme Research
Tokushima University

In Japanese

Development of human elastic cartilage using a novel 3D cell culture system

Prof. Hideki Taniguchi

Professor
Yokohama City University

In Japanese

Clinical exploration of innovative functional proteins, "Silk Elastin"

Dr. Shingo Kawabata

unit manager
Planning Dept. Biotechnology&Medical Division
Sanyo Chemical Industries, Ltd

In Japanese

Compact, lightweight and affordable hand rehabilitation robot - SMOVE

Dr. Jyumpei Arata「

Associate Professor
Department of Mechanical Engineering, Faculty of Engineering
Kyusyu University

In Japanese

Organizer

Oct.10(Thu.)      15  :  00  ~  16  :  30

F201
【O-8】 Genome Editing (tentative)
Admission Fee required Pre-Registration required Simultaneous interpretation

Genome Editing (tentative) 

Coordinator


Development of Base editing technology and its future

Prof. Keiji Nishida

Professor
Engineering Biology Research Center
Kobe University

In Japanese


Gene therapy and Genome editing approach for hemophilia

Prof. Tsukasa Ohmori

Professor
Department of Biochemistry
Jichi Medical University

In Japanese

Dr. Sesquile Ramon

Director
Science and Regulatory Affairs
Biotechnology Innovation Organization

Organizer

Oct.10(Thu.)      15  :  00  ~  16  :  45

F204
【O-9】 Forefront of Biopharmaceutical Manufacturing
Admission Fee required Pre-Registration required Simultaneous interpretation

Forefront of Biopharmaceutical Manufacturing  

Coordinator

Kobe University Graduate School of Science, Technology and Innovation

Dr. Parrish Galliher

Chief Technical Officer,
GE Healthcare Life Sciences

“The Future of Monoclonal Antibody Bio manufacturing”

Dr. Kasper Møller

Chief Technical Officer,
AGC Biologics


Applying GMPs to the Biopharmaceutical Manufacturing Supply Chain - An industry collaborative approach to defining best biopharmaceutical practices which are necessary to ensure the safety of the supply chain

Mr. Simon Chalk

Director and Founder,
BioPhorum Operations Group

Oct.11(Fri.)      10  :  00  ~  11  :  00

F204
【S-18】 Ablexis & AlivaMab Discovery Services
Pre-Registration required

Superior quality, speed and value in antibody drug discovery with AlivaMab Mouse and AlivaMab Discovery Services 

Successful, fast movement from Discovery to Clinical Development is more important than ever in capturing value. Ablexis' AlivaMab(TM) Mouse technology brings quality, speed and value in generating development-ready antibodies that meet your target product profile, making it the best in class platform for antibody drug discovery and development. AlivaMab Mouse avoids the false economies of the other available platforms - transgenic, in vitro and humanization.

For outsourcing therapeutic antibody discovery, AlivaMab Discovery Services ("ADS") provides exceptional capabilities in antibody drug discovery. The scientists at ADS have decades of experience in antibody drug discovery, assay development and recombinant antibodies. The team will be your collaborative partners, and will deliver superior quality, speed and value for your project. Today's presentation will review classes of antibody drug discovery platforms, then present the AlivaMab Mouse and finish with case studies in antibody drug discovery at AlivaMab Discovery Services.

Superior quality, speed and value in antibody drug discovery with AlivaMab Mouse and AlivaMab Discovery Services

Dr. Larry Green

Ablexis & AlivaMab Discovery Services

Oct.11(Fri.)      11  :  45  ~  12  :  45

F202
【S-20】 Australian Embassy (Australian Trade and Investment Commission)
Pre-Registration required

Life Science Research and Clinical Trials Environment in Australia  

Australia has a vibrant life science ecosystem of medical technology, biotechnology and pharmaceutical companies and research organisation.
There are around 140 life science companies listed on the Australian Stock Exchange (ASX). Over 500 medtech companies have products listed on the Australian Register of Therapeutic Goods and around 50 multinational pharmaceutical companies and 400 locally-owned medical biotechnology companies operate in Australia. Australia also has a thriving research industry with particular strengths in immuno-oncology, tropical and infectious diseases and drug development through artificial intelligence. Between 2001 and 2010, Australia ranked sixth in the world in terms of overall output of health and medical publications. In 2016, Scientific American Worldview ranked Australia fifth for innovation.
Australia's Government is committed to supporting commercial activity and research. The Government invests around $3 billion each year on supporting medical research projects and enhancing Australia's research infrastructure. In addition, the Government ensures streamlined regulatory processes and attractive tax reforms. These factors have helped make Australia an internationally renowned destination for clinical trials, with 1,000 new trials commenced in Australia annually.
In this seminar, we introduce the Australian delegates participating at BioJapan 2019, and outline the life science industry sector and clinical trials environment in Australia.

Coordinator

Mr. David Lawson

Senior Trade Commissioner
Australian Trade and Investment Commission

TBC

Clinical Trials Environment in Australia

Dr. Dan Grant

MTP Connect

Luncheon

Oct.11(Fri.)      12  :  00  ~  13  :  30

F205-206
【L-8】 Life Innovation Area Conference
Pre-Registration required

 

Coordinator

Mr. Mitsuru Miyata

CEO
Miyata Institute of Technologies

Dr. Kazuhiro Sakurada

Deputy Program Director
Medical Sciences Innovation Hub Program
RIKEN

In Japanese

Prof. Hiroaki Miyata

Professor
School of Medicine
Keio University

In Japanese

Prof. Takeharu Yamanaka

Professor (Director, Center for Data Science)
Department of Biostatistics
Yokohama City University

In Japanese

Mr. Kiyoshi Sato

Vice President Advanced Research Center
Shiseido

In Japanese

Mr. Akihiro Maki

Associate Director
Medical Company
Johnson & Johnson K.K.

In Japanese

Organizer

Oct.11(Fri.)      13  :  30  ~  15  :  00

F201
【O-13】 Nucleic Acid Drugs
Admission Fee required Pre-Registration required Simultaneous interpretation

Recent progress of nucleic acid drugs: stabilization, DDS, and manufacturing technologies 

Nucleic acid drugs are expected as a new modality of next-generation medicines, and many of them are close to commercialization. In addition to antisense nucleic acids, development of siRNAs are now in progress. In this session, we will review the recent progress of nucleic acid drugs. In particular, we will focus on stabilization, DDS, and manufacturing technologies.

Coordinator

Prof. Takeshi Wada

Professor
Faculty of Pharmaceutical Sciences
Tokyo University of Science

Control of backbone stereochemistry provides a new dimension for the optimization of oligonucleotide drug candidates

Dr. Naoki Iwamoto

Director
Drug Discovery
Wave Life Sciences

Dr. Muthiah Manoharan

Senior Vice President,
Alnylam Pharmaceuticals

Antisense Oligonucleotide, Nusinersen, for Spinal Muscular Atrophy

Kazutaka Ogiwara

Medical Manager
Medical
Biogen Japan Ltd.

In Japanese

Prof. Takanori Yokota

Professor
Department of Neurology and Neurological Science
TMDU

Oct.11(Fri.)      13  :  45  ~  14  :  45

F205-206
【S-22】 TAKARA BIO INC.
Pre-Registration required

Development of novel engineered T cell therapies 

Prof. Naoto Hirano

Associate Director for Research, Tumor Immunotherapy Program, Senior Scientist / Professor of Medicine
Princess Margaret Cancer Centre / Department of Immunology, University of Toronto

In Japanese

Prof. Kazuhiro Kakimi

Professor
Department of Immunotherapeutics, The University of Tokyo Hospital

In Japanese

Oct.11(Fri.)      13  :  45  ~  14  :  45

F203-204
【S-21】 Johnson & Johnson Innovation
Pre-Registration required Simultaneous interpretation

Open Innovation Model and cotrubution to heathcare ecosystem buidling at Johnson and Johnson 

Coordinator

Dr. JUN KUSUNOKI

Director, New Ventures Japan
Asia Pacific Innovation Center
Johnson and Johnson INNOVATION

TBC

Ms.

TBC

Organizer

Oct.11(Fri.)      15  :  30  ~  17  :  00

F201
【O-15】 Engineered T-Cell Therapy -Bench to Bedside-
Admission Fee required Pre-Registration required Simultaneous interpretation

Engineered T-Cell Therapy -Bench to Bedside- 

The first two CAR-T cell therapies were approved in 2017 in US, and now on the market from the following year. Also in Japan, one of the two therapies was approved and its price has been set earlier this year, to be a commercially available treatment. Under the positive circumstances worldwide, development of novel CAR-T cell therapies, as well as TCR-T cell therapies utilizing the similar technology, are being enhanced all the more.
In this seminar, we will focus on some examples of such engineered T-cell therapies; 1) allogenic CAR-T which utilize T cells from donors, 2) a case from China (now becoming a major hot spot of CAR-T development), which succeeded in out-license to a global pharma, and 3) clinical development of TCR-T cell therapy in Japan, to share and discuss expectations on commercialization in the near future.

Coordinator

Mr. Masanobu Kimura

Director, President of Gene Therapy Business Unit
Takara Bio Inc.

Prof. Waseem Qasim

Cell and Gene Therapy
University College London

Competition and Breakthrough in the Space of BCMA Targeted Immunotherapy for Myeloma

Dr. Frank (Xiaohu) Fan


Luncheon

Oct.9(Wed.)      12  :  00  ~  13  :  00

F202
【L-2】 Embassy of Canada to Japan
Pre-Registration required

“Power of Human Cells - Future of Medicine: Opportunities in Canada“ (TBC) 

Canada is one of the leaders in regenerative medicine innovation. Since the team of Drs. James Till and Ernest McCulloch discovered the stem cell in 1961, Canada has been a hotbed of ground-breaking innovations in regenerative medicine. One such example is the work of Dr. John E. Dick of Toronto University, who received the prestigious Keio Medical Science Prize for his research on cancer stem cells in 2017.
Canada's support of a wide range of research and development and commercialization of research in regenerative medicine through investment at the federal and provincial levels combined with various tax incentives and the availability of highly educated talent, makes Canada an attractive destination for your business and investment.
This seminar will provide an overview of an unique national funding program, NRC Health Challenge Program, to support high risk, high reward R&D of disruptive technologies in cell therapy and gene therapy. The seminar will feature the Program Director of the Health Challenge Program.
We look forward to seeing you!

Opening Remarks

Mr. Iain Stewart

President
National Research Council Canada

NRC Health Challenge Program - Disruptive technology solutions for accessible cell and gene therapies: Opportunities in Canada

Dr. Kelley Paratao

Program Director
the Health Challenge Program
National Research Council Canada

Oct.9(Wed.)      13  :  00  ~  14  :  00

F204
【S-3】 Hitachi, Ltd. / Hitachi Group
Pre-Registration required

Constructing ecosystem for industrial utilization of iPS cells 

iPS cells are expected to be powerful tools for drug discovery as well as for regenerative medicine. In Europe and the US, iPS cell banks are being developed for drug discovery, and their use in drug discovery is becoming active. On the other hand, although Japan is ahead of regenerative medicine, it is urgently important for pharmaceutical companies to set up an "Ecosystem for industrial utilization of iPS cells" that accelerates drug discovery.
Towards realization, investigation and construction of frameworks that can be provided by disease-specific iPS cells and iPS cells from healthy persons, construction of a system capable of stably supplying high-quality cells, analysis of the current state over the world, and cooperation systems with other cell banks are required. Therefore, members of industry, government, and academia are discussing issues and solutions at COCN (Council on Competitiveness-Nippon).
This time, we invited lecturers from academia and industry to be active in the front line. They are going to give lectures on understanding of the current situation and expectations for the future toward constructing an industrial use ecosystem of iPS cells for drug discovery.

Coordinator

Dr. Jun Otomo

Chief Engineer
Advanced Medical Solution Center, Analytical Systems Division, Healthcare Business Unit
Hitachi, Ltd.

Application of disease iPS cells for elucidation of disease psychopathology and drug discovery

Dr. Megumu Saito

Associate professor
Clinical Application Department
Center for iPS cell research and application (CiRA) Kyoto University

In Japanese

Current status and prospects of drug discovery using human iPS cells in pharmaceutical industry

Dr. Yuya Kunisada

Associate Director
Research Neuroscience Drug Discovery Unit Innovative Biology Laboratories
Takeda Pharmaceutical Company Limited

In Japanese

Oct.9(Wed.)      14  :  00  ~  15  :  00

F203
【S-5】 LONZA JAPAN LTD.
Pre-Registration required Simultaneous interpretation

Entering a new era of cell & gene therapies: industrialization of manufacturing  

- Challenges: cost, quality, speed, reliability
- Needs: standardization, end-to-end processes & chain of custody
- Solutions: Technology platforms, regulatory frameworks

Mr. Alberto Santagostino

Senior Vice President, Head of Cell and Gene Technologies
Lonza Pharma & Biotech

Organizer

Oct.9(Wed.)      15  :  45  ~  17  :  15

F205-206
【O-4】 Regenerative Medicine Toward Development and Commercialization
Admission Fee required Pre-Registration required Simultaneous interpretation

Regenerative Medicine
Toward Development and Commercialization 

In 2019, various companies plan to launch regenerative medicine products and existing commercial products of regenerative medicine also conducts life cycle management. Industries are interested in commercial products' activities, such as development, challenges and activities to solve during review period, strategy and current situation at port marketing, and so on. This symposium invites speakers from companies, which has regenerative medicine products approved in 2019 and are facing actual industrialization of regenerative medicine. Then this symposium expects that the audience can feel positive future for regenerative medicine.

Coordinator

Mr. Atsuji Hirota

Chair,Public Affairs Committee
Forum for Innovative Regenerative Medicine

JAPAN’S FIRST GENE THERAPEUTIC DRUG, COLLATEGENE, TREAT CRITICAL LIMB ISCHEMIA

Dr. Ei Yamada

President & CEO
AnGes, Inc.

In Japanese

Commercializing CAR-T Cell Therapy in Japan

Mr. Michitaka Nakao

Head
Cell & Gene Franchise, Oncology Business Unit
Novartis Pharma KK

In Japanese

Organizer

Oct.10(Thu.)      10  :  00  ~  11  :  30

F205-206
【O-5】 Cell Therapy Manufacturing: Challenges and Solutions
Admission Fee required Pre-Registration required Simultaneous interpretation

Cell Therapy Manufacturing: Challenges and Solutions 

While recent progress in regenerative medicine space, manufacturing of cell therapy products has many issues that need to be sorted out.
Cooperation among all stakeholders is vital for future progress. In this session, we will organize a panel discussion by 4 leading experts in this space from different sectors that include product development, contract manufacturing, cell source supply and regulatory issue. They will show their current efforts and discuss future perspectives.

Coordinator

Mr. Kunihiko Suzuki

Vice Chairman
Forum for Innovative Regenerative Medicine

iPS cell stock project for regenerative medicine

Prof. Naoko Takasu

Professor and Deputy Director, Head of the Medical Applications Promoting Office
Medical Applications Promothing Office/Facility for iPS Cell Therapy
Center for iPS Cell Research and Application,Kyoto University

In Japanese

Solutions for Manufacturing Regenerative Medicine in Rapidly Expanding Industry as Global CDMO

Mr. Kazuchika Furuishi

Deputy General Manager
Regenerative Medicine Business Sector, Life Science Business Headquarters
Hitachi Chemical Co., Ltd.

In Japanese

Challenges for manufacture of Allogeneic regenerative medicine product

Dr. Kiwamu Imagawa

Director
Research Division, Regenerative Medicine
JCR Pharmaceuticals Co.,Ltd

In Japanese

Regulatory challenges in manufacturing of cell therapy products in Japan

Dr. Yoji Sato

Head, Division of Cell-Based Therapeutic Products
Division of Cell-Based Therapeutic Products
National Institute of Health Sciences

In Japanese

Luncheon

Oct.10(Thu.)      12  :  00  ~  13  :  00

F204
【L-5】 RORZE Lifescience Inc.
Pre-Registration required

Introduction on mechanization/automation of cultured epidermis for vitiligo treatment in China  

Introduction on mechanization/automation of cultured epidermis for vitiligo treatment in China

Mr. Uyama Taro

Dr. Uyama Taro

RORZE ReMed Lifescience Co.Ltd

In Japanese

Oct.10(Thu.)      13  :  30  ~  14  :  30

F201
【S-14】 Knagawa Prefecture
Pre-Registration required

"Kanagawa Life Innovation Center:
A Strategic Open Innovation Base for Regenerative Medicine and Cell Therapy Industry"  

Dr. Masaya Nakamura

Professor
Department of 0rthopaedic Surgery
Keio University Shool of Medicine

In Japanese

Mr. Yoji Satoh

Division of Cell Based Therapeutic Products
National Institute of Health Science

In Japanese

Mr. Toshio Fujimoto

General Manager
Takeda Pharmaceutical Co., Ltd Shonan Health Innovation Park

In Japanese

Mr. Yoshiyuki Makino

Kanagawa Prefecture

In Japanese

Mr. Ryota Yoshimoto

Keio University

In Japanese

Organizer

Oct.10(Thu.)      16  :  00  ~  17  :  00

F205-206
【O-10】 Update in iPS Cell Research
Admission Fee required Pre-Registration required Simultaneous interpretation

Update in iPS Cell Research 

Prof. Shinya Yamanaka, a developer and Nobel Prize winner, talks about the progress of research and development of iPS cells, an innovative innovation originated in Japan. Discuss how to bring the fruits of iPS cells research to patients to realize their happiness.

Coordinator

Mr. Mitsuru Miyata

CEO
Miyata Institute of Tecnologies


Organizer

Oct.11(Fri.)      10  :  00  ~  11  :  30

F205-206
【O-12】 Issues in the rapid industrialization of regenerative medicine
Admission Fee required Pre-Registration required Simultaneous interpretation

Issues in the rapid industrialization of regenerative medicine  

The Forum for Innovative Regenerative Medicine (FIRM) will publish its mid-term report in 2019,
and the priority issues in its report are exactly the issues/challenges facing the regenerative medicine industry.
In this session, we share the industry's efforts and also introduce their activities for promoting the industrialization and perspectives. The session presents lectures, followed by panel discussion with stakeholders to further clarify the guidepost for establishing and promoting the regenerative medicine industry.

Coordinator

Mr. Hironoshin Nomura

Senior Analyst
Equity Research
Mizuho Securities Co.,Ltd.

"FIRM VISION 2025" toward Industrialization of Regenerative Medicine.

Dr. Ken-Ichiro Hata

Representative Director,Chairman
Forum for Innovative Regenerative Medicine

In Japanese

Trends and challenges on industrialization of cell and gene therapy

Mr. Ryo Hanamura

Principal
Arthur D. Little Japan

In Japanese

World policies and R&D trends in cell therapy

Mr. Masahiro Tsuji

Fellow
Center for Research and Development Strategy, Life Science and Clinical Research Unit
Japan Science and Technology Agency

In Japanese

Luncheon

Oct.11(Fri.)      12  :  00  ~  13  :  00

F201
【L-6】 Keio University Tonomachi Town - Campus
Pre-Registration required

Cell production and Quality evaluation Ecosystem in TONOMACHI
~One-stop support service from seeds to clinical evaluation~
 

Coordinator

Mr. Ryota Yoshimoto

Special professor
Wellbeing Research Center
KEIO University

Mr. Masaya Nakamura

KEIO University

In Japanese

Mr. Chikafumi Yokoyama

ReproCELL Inc.

In Japanese

Mr. Jun Kawai

RIKEN(Institute of Physical and Chemical Research)

In Japanese

Panel Session

Akira Takakura

CIEA(Central Institute for Experimental Animals)

In Japanese

Organizer

Oct.11(Fri.)      10  :  15  ~  11  :  45

Main Stage
【M-4】 Food Creates Health with Detecting Conditions Ahead
Pre-Registration not required

Food Creates Health with Detecting Conditions Ahead Sick (tentative) 

Coordinator


Dr. Keiko Abe

Prof. Katsuya Iijima

Dr. Asuka Kamei

Researcher
Group for Food Functionality Assessment
Kanagawa Institute of Industrial Science and Technology

In Japanese

Luncheon

Oct.11(Fri.)      12  :  00  ~  13  :  30

F203-204
【L-7】 Shonan Health Innovation Park
Pre-Registration required Simultaneous interpretation

Creation of innovation community open to the world ―challenge of shonan iPark with entrepreneurs— 

Dr. Fujimoto Toshio

General Manager
Shonan Health Innovation Park

In Japanese

Organizer

Oct.11(Fri.)      15  :  30  ~  17  :  00

F202
【O-16】 Healthcare Industrial Strategy with comprising Insurance Companies (tentative)
Admission Fee required Pre-Registration required Simultaneous interpretation

Healthcare Industrial Strategy with Insurance Companies  

Japanese Insurance companies have entered the healthcare business since last year. New types of life insurance have been born that aim to improve the health of subscriber ssuch as accompanying insurance. Japanese citizens pay almost the same life insurance premiums as medical expenses. Based on the progress of life science and mobile health, I would like to discuss healthcare business strategies that insurance companies should aim for.

Coordinator

Mr. Mitsuru Miyata

CEO
Miyata Institute of Technologies

Shared-Valued Insurance SUMITOMO LIFE Vitality ~ Beyond the Insurance ~

Mr. Daisuke Amamiya

Manager
Vitality Business Marketing Sect.
SUMITOMO LIFE INSURANCE COMPANY

In Japanese


In Japanese

Healthcare Business"No one will be left behind"

Mr. yoshinori kamiya

General Manager
Marketing planning Department Healthcare Business Development Team
Nippon Life Insurance Company

In Japanese

Challenge to the future medicine by Tohoku Medical Megabank

Professor / Deputy of Executive Director
Tohoku University, Graduate School of Information Sciences / Tohoku Medical Megabank Organization

In Japanese

Oct.9(Wed.)      13  :  15  ~  14  :  15

F202
【S-2】 The National Institute of Advanced Industrial Science and Technology (AIST)
Pre-Registration required

Our challenge to develop next-generation bioproduction
: Formation of a bioeconomy hub 

AIST has been playing a leading role in area of research and development of bioproduction in Japan, developing technologies for tightly-sealed plant factory and production of biological medicine, and promoting research in bioinformatics using genome data. Bioproduction system that utilizes biological function for material production, remains designated as one of the nine pillars in "Bio-strategy 2019", developed for the first time in ten years. As AIST is expected to function as a bioeconomy hub, we endeavor to strengthen our position by further developing relevant technologies. In this session, we would like to introduce the present state as well as the prospects of spreading the bioproduction that utilizes a broad range of biomass from microorganisms, animals, as well as plants.

Coordinator

Dr. Koyomi Miyazaki

Director
Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology (AIST)

Engineered transcription factor for made-of-order plant breeding

Dr. Shingo Sakamoto

researcher
Bioproduction Research Institute, AIST

In Japanese

−Too good for food and fuel−
Euglena's craftsmanship of fine chemicals

Dr. Motonari SHIBAKAMI

Senior Researcher
Biomedical Research Institute, AIST

In Japanese

"Golden eggs" laid by genome-edited hens: cost-effective, large-scale production of recombinant proteins using chicken egg bioreactors

Dr. Isao Oishi

Research Group Reader
Biomedical Research Institute, AIST

In Japanese

Oct.10(Thu.)      14  :  30  ~  17  :  00

F203
【S-16】 Japan Science and Technology Agency (JST)
Pre-Registration required

Game-changing technology for low-carbon society and bioeconomy 

Methane/methanol conversion by the innovative bioprocess using microbial gas-phase reaction

Dr. Masahito Ishikawa

Assistant Professor
Department of Biomolecular Engineering, Graduate School of Engineering
Nagoya University

In Japanese

Enhanced aquatic plant biomass production utilizing mutualistic microorganisms

Prof. Masaaki Morikawa

Professor
Graduate School of Environmental Earth Science
Hokkaido University

In Japanese

Robust and low-cost microbial fermentation based on high-temperature fermentation technology

Prof. Kazunobu Matsushita

Advisory director
Research center for thermotolerant microbial resources RCTMR
Yamaguchi University

In Japanese

Challenge to Smart Cell Development by Integration of Biotechnology and Digital Technology

Prof. Tomohisa Hasunuma

Director and Professor
Engineering Biology Research Center
Kobe University

In Japanese

Molecular breeding of plant for wood biomass engineering

Dr. Nobutaka Mitsuda

Group Leader
Bioproduction Research Institute
National Institute of Advanced Industrial Science and Technology (AIST)

In Japanese

An innovative technology for plant size enhancement and control: Artificial control of the cytoplasmic streaming

Dr. Motoki Tominaga

Associate professor
Faculty of Education and Integrated Arts and Sciences
Waseda University

In Japanese

Promotion of photosynthesis and plant productivity by controlling stomatal aperture

Prof. Toshinori Kinoshita

Professor
Institute of Transformative Bio-Molecules
Nagoya University

In Japanese

Oct.11(Fri.)      10  :  00  ~  11  :  30

F201
【S-19】 National Institute of Technology and Evaluation
Pre-Registration required

Microbiology meets digital biology - an effort to promote Bioeconomy - 

Prof. Kamagata Yoichi

Life Science and Biotechnology research base
National Institute of Advanced Industrial Science and Technology

In Japanese

Mr. Sakamoto Yuji

Japan Association of Bioindustries Executives (JABEX)

In Japanese

Prof. Susumu Goto

Professor
Database Center for Life Science (DBCLS), Research Organization of Information and Systems (ROIS)

In Japanese

Oct.11(Fri.)      15  :  00  ~  17  :  00

F203-204
【S-23】 New Energy and Industrial Technology Development Organization
Pre-Registration required Simultaneous interpretation

NEDO seminar: Forefront of plant biotechnology for useful material production 

New trends in production of useful compounds by plant and plant tissue cultures

Prof. Toshiya Muranaka

Professor
Graduate School of Engineering
Osaka University

In Japanese

Development of an efficient production system for pharmaceutical intermediate 10-DAB using yew-tree smart cells

Mr. Homare Tabata

Hokkaido Mitsui Chemicals, Inc.

In Japanese

Transport/accumulation technologies supporting valuable metabolite production in plants

Prof. Kazufumi Yazaki

Professor
Research Institute for Sustainable Humanosphere
Kyoto University

In Japanese

Development of a novel genome editing tool for plant genome engineering

Prof. Keishi Osakabe

Professor
Graduate School of Technology, Industrial and Social Sciences
Tokushima University

In Japanese

Activity for the diffusion of "Smart Cell Technologies"

New Energy and Industrial Technology Development Organization

In Japanese

Organizer

Oct.11(Fri.)      10  :  00  ~  11  :  30

F202
【O-11】 Innovation in Healthcare by Digital Technologies : Diagnosis and Therapy
Admission Fee required Pre-Registration required Simultaneous interpretation

Innovation in Healthcare by Digital Technologies : Diagnosis and Therapy 

Digital technology in healthcare is changing the platforms of disease diagnosis, prevention and therapy. In the diagnosis of neuropsychiatric disorders including dementia such as Alzheimer's disease, imaging such as MRI and artificial intelligence (AI) is expected for clinical trials and early diagnosis. In addition, digital therapeutics (DTx), which utilizes digital technology for therapeutic intervention, has also been tried in areas of hypertension, diabetes mellitus, and psychoneurological diseases. DTx using smartphone applications and IoT devices can promote behavior changes in patients and open the way to prevention. However, the establishment of an ecosystem will be a challenge to involve a wide range of stakeholders, including the pharmaceutical industry, regulatory authorities, healthcare professionals, and patients, as well as companies participating in digital technology innovation. In this seminar, the utilization of digital technology in healthcare and the scalability in diagnosis and therapy will be presented.

Coordinator

Dr. WATARU TAKASAKI

Corporate Officer, Head of R&D Division
R&D Division
Daiichi Sankyo Co., Ltd.

Commercialization of AI-based CADx (Computer Aided Diagnose) program for diagnosis and classification for central nervous system diseases using brain MRI images

Mr. NOTSU Yoshiyuki

Director, Chief Development Officer
ERISA Co., Ltd.

In Japanese

Novel Digital Technologies for Diagnosis of Neuropsychiatric Disorders at King's College London, UK

Dr. Chris Kalafatis

Consultant in Old Age Psychiatry
Clinical Trials - Institute of Psychiatry,Psychology and Neuroscience (IoPPN), KCL
King's College London / South London & Maudsley NHS Trust , UK

Mr. Hisashi Miyata

Chief Operating Officer
CureApp,Inc.

In Japanese

DTx: Pursuing the Next Phase of Industry Evolution

Dr. Megan Coder

Executive Director
Digital Therapeutics Alliance

Organizer

Oct.11(Fri.)      13  :  30  ~  15  :  00

F202
【O-14】 Emerging Digital Startups in Medical Area
Admission Fee required Pre-Registration required Simultaneous interpretation

Emerging Digital Startups in Medical Area 

In the medical area, digital startups are emerging and got attentions. In this session, the trend and challenge of startups in medical and healthcare area, and support and incubation of startups are addressed with the leaders in this industry. Featured startups are introduced, and how the data analysis and AI are applied for medical area, and concrete examples and future development are discussed.

Coordinator

Dr. Tomy Kamada

CEO
TomyK Ltd.

Dr. Takahiro Uchida

CEO
Japanese Organization for Medical Device Development, Inc.

In Japanese

Mr. Hiroaki Kitano

President & CEO
Sony Computer Science Laboratories Inc.

High-content and high-throughput drug screening platform by machine learning-driven image-based cell sorting technology

Mr. Waichiro Katsuda

CEO
ThinkCyte

In Japanese

Mr.

CEO
MICIN Inc,

In Japanese

Toward patient-oriented drug development

Yasuaki Hasebe

CEO
Activaid Inc

In Japanese

Organizer

Oct.10(Thu.)      10  :  30  ~  12  :  30

Main Stage
【M-2】 Bioeconomy(1) Life Cycle Design and Policy for Circular Economy
Pre-Registration not required Simultaneous interpretation

Transformation of business models in a circular economy 

The concept of the circular economy is reflected not only in environmental policies that address resource depletion and environmental load reduction, but also in growth strategies for creating new businesses, especially in Europe. The introduction of renewable energy for a decarbonized society is a global request after the Paris Agreement, and is linked to the circular economy. In this seminar, we will deepen discussions on the transformation of business models in relation to Japan's environmental policy.

Coordinator

Prof. Daisuke Shibata

Specially Appointed Professor
Research Institute for Sustainable Humanosphere, Kyoto University

(tentative) The concept of “Circulating and Ecological Economy (CEE)” and relationship with the bio industry

Mr. Tokutaro Nakai

Director-General for Environmental Policy
Ministry of the Environment,Government of Japan

In Japanese

Effects of circular economy on manufacturing business

Prof. Yasushi Umeda

Professor
Research into Artifacts, Center for Engineering, School of Engineering
the University of Tokyo

In Japanese

Yukari TAKAMURA

Professor
Institute for Future Initiatives
The University of Tokyo

Dr. Hirofumi Aizawa

Organizer

Oct.10(Thu.)      13  :  00  ~  15  :  00

Main Stage
【M-3】 Industry Initiatives for Clean Oceans
Pre-Registration not required Simultaneous interpretation

Towards a Circular Economy for Plastics - Challenges to Marine Plastic Pollution 

Coordinator

Prof. Yasuo Ohnishi

Department of Biotechnology, Graduate School of Agricultural and Life Sciences, The University of Tokyo

Japan's efforts to overcome marine plastic litter issue

TBC

Dr. Shunsuke Sato

ASSISTANT MANAGER
Bioproducts Research Group, Biotechnology Research Laboratories, Pharma & Supplemental Nutrition Solutions Vehicle
KANEKA CORPORATION

In Japanese

Can bioplastics be a solution? -Environmental conscious materials of Mitsubishi Chemical-

Dr. Hiroshi Sano

Adviser to General Manager
Advanced Polymers Planning Departmet
Mitsubishi Chemical Corporation

In Japanese

The domestic and international circumstances surrounding plastics and “Resource Circulation Strategy for Plastics”

Mr. TOMOYUKI IZUMI

Deputy Director
Office for Recycling Promotion, Environment Regeneration and Resource Circulation
Ministry of the Environment

In Japanese

Kao’s environmental approach to plastic containers and packaging

Mr. Inaba Shinichi

Senior Manager
Packaging Technology Research
Kao Coprporation

In Japanese

Organizer

Oct.9(Wed.)      14  :  30  ~  17  :  00

F202
【A-1】 Japan Bioindustry Award, Bioindustry Research Award 2019 Ceremony, Award Lecture
Pre-Registration required Simultaneous interpretation

Japan Bioindustry Award, Bioindustry Research Award 2019 Ceremony, Award Lecture 

Japan Bioindustry Association (JBA) celebrated the 30th anniversary of its foundation in 2017. Concomitantly with this anniversary, JBA evolved previous awards to newly established "Japan Bioindustry Award" and "Bioindustry Research Award". The Japan Bioindustry Award is given to an incomparable work which has contributed significantly to bioindustry's development or envisaging significant industry development in near future.The Bioindustry Research Award is given to young researchers engaged in outstanding research activities appreciating practical application potentials.
This is the third time to celebrate, that is getting more and more exciting. The award ceremony of these two Awards is going to be held on this occasion and the award lecture by the winners of the Japan Bioindustry Award will be followed. The poster session by the winners of the Bioindustry Research Award will be held after the award lecture.

Biodegradable plastic with marine degradability: research on microbial production system and development of large-scale production

Prof. Yoshiharu Doi

Professor Emeritus
Tokyo Institute of Technology

In Japanese

Mr. Tetsuya Fujiki

Manager
Corporate Research & Business Planning Department
KANEKA CORPORATION

In Japanese

Organizer

Oct.10(Thu.)      10  :  30  ~  12  :  30

Open Stage
【OP-1】 Biocluster Summit 2019 - Ecosystem -
Pre-Registration not required

Biocluster Summit 2019 - Bio-Ecosystem in each country and future collaboration - 

We will focus on the formation of Bio-Ecosystems, which is an issue in "Biostrategy 2019", introduce and confirm trends in each country, explore the possibility of future collaborations, and at the same time lead to future biostrategy action plans in Japan.

Coordinator

Dr. TSUNEAKI SAKATA

Chairman/ Deputy Chairman
All Japanese Bio Regions Committee /All Japanese Bio Regions Committee

Mr. Nao Yoshizawa

Attorney at Law / Patent Attorney
Uruma Law Offices

MedCity

Israel's ecosystem at a glance

Ms. Noa Asher

Economic Minister. Head of Economic and Trade Mission

Mr. LEE Chee How

Regional Director, Tokyo Office
EDB Singapore

USA Life Science Ecosystem and International Partnerships

Mr. Joe Panetta

President & CEO
Executive Office
BIOCOM

Creating innovation hotspot in life science in Japan

Dr. Toshio Fujimoto

General Manager
Shonan Health Innovation Park

Dr. Tsuneaki Sakata

Kinki Bio-industry Development Organization

Oct.10(Thu.)      12  :  45  ~  15  :  45

F205-206
【S-13】 City of Yokohama
Pre-Registration required Simultaneous interpretation

RBC YOKOHAMA Program Pitching Event (Yokohama Day)
The pitches will be given by the US and European companies (in the field of Regenerative Medicine, Pharmaceuticals, etc.) aiming to expand into the Japanese market and Japanese companies that have graduated from the acceleration program of the entrepreneur support group CONNECT in San Diego, USA. We’d like you to take advantage of this opportunity and find your new business partners. 

The pitches will be given by the leading companies in US and Europe (in the field of Regenerative Medicine, Pharmaceuticals, etc.) aiming to develop and expand into the Japanese market.
They will come to Japan based on the invitation program for foreign-affiliated companies "Regional Business Conference" conducted by the City of Yokohama with the support of JETRO and the Ministry of Economy, Trade and Industry.
And the pitches will be given by Japanese companies that have graduated from the acceleration program of the entrepreneur support group CONNECT in San Diego, USA. We will have a time for networking after this pitching event, so we'd like you to take advantage of this opportunity and find your new business partners.

TBC

Oct.11(Fri.)      10  :  00  ~  11  :  00

F203
【S-17】 Intellectual Property Strategy Network, Inc
Pre-Registration required


Success of bio-venture and its factors 

Many bio-ventures have been established and gone out, however there exist a quite few big-successful bio-ventures over the world. The definition of successful ventures may be M&A, or to become large pharmaceutical companies as EXIT, but the success rate is roughly estimated about 0.5 to 1.0% depending on US-BIO data. Compared with the recent success rate of 5.0% of each project at major pharmaceutical companies in Japan, USA and Europe, the efficiency is considerably low.
Therefore, in order to increase the success rate of the bio-ventures as much as possible, learning success cases and using failure cases as lessons, well-known experts from INCJ, Daiichi-Sankyo and FCR Partners identify the main issues and analyze success / failure factors from various angles, then we would like to find out some common terms and special terms out of them for the audience.
We hope that this lecture will contribute to the development of bio-ventures by providing some hints that can increase the success rate of bio-ventures in Japan.

Financing of drug discovery & development startups in Japan

Mr. Koichi Ashida

Executive Managing Director
INCJ, Ltd(Under process of permission)

In Japanese

「Venture, university and pharma industry, their own contribution」

Mr. Kazuo Sato

Corporate Advisor
Daiichi Sakyo Co., Ltd.

In Japanese

Global Investors’ eyes
Awareness of Intellectual Properties
Project Management
“Dentsu’s 10 Working Guidelines” to “8 questions”

Mr. Yasuo Horikoshi

Managing Director,Head of Investment Department / Part-time Advisor
Investment Department
FCD PARTNERS INC. / Intellectual Property Strategy Network, Inc.

In Japanese

Oct.9(Wed.)      13  :  00  ~  15  :  30

F205-206
Ministry of Health, Labour and Welfare
Pre-Registration required Simultaneous interpretation

 

Mr. Benjamin Wiegand

Oct.9(Wed.)      13  :  00  ~  15  :  30

F205-206
Ministry of Health, Labour and Welfare
Pre-Registration required Simultaneous interpretation

 

Mr. Thorsten Rall

Oct.9(Wed.)      13  :  00  ~  15  :  30

F205-206
Ministry of Health, Labour and Welfare
Pre-Registration required Simultaneous interpretation

 

In Japanese

Sakakibara Akira

Oct.9(Wed.)      13  :  00  ~  15  :  30

F205-206
Ministry of Health, Labour and Welfare
Pre-Registration required Simultaneous interpretation

 

In Japanese

Mr. Tomotaka Goji

Oct.9(Wed.)      13  :  00  ~  15  :  30

F205-206
Ministry of Health, Labour and Welfare
Pre-Registration required Simultaneous interpretation

 

In Japanese

Mr. Taihei Tanaka

Luncheon

Oct.10(Thu.)      11  :  15  ~  13  :  45

F203
【L-4】 Flanders Investment & Trade
Pre-Registration required Simultaneous interpretation

 

The 20th Flanders Life Sciences Seminar in Yokohama

Flanders Investment & Trade

Life Sciences in Flanders, a story of Science, Business and continuous Growth

Mr. Willem Dhooge

flanders.bio

AESCULAPE CRO Belgium bvba

Mr. Jean-Paul Deslypere

AESCULAPE CRO Belgium bvba

InnoSer Belgie

Dr. Jan Bartels

InnoSer Belgie

Game-Changing Medical Devices for optimizing accuracy of drug delivery and the quality of diagnostic assays

Ms. Danielle Pasmans

Novosanis

De Clercq & Partners: a top tier firm for intellectual property matters in Europe

Dr. Andrej MICHALÍK

De Clercq & Partners

NEWTON BIOCAPITAL PARTNERS SPRL

Dr. Toshiyuki Mori

NEWTON BIOCAPITAL PARTNERS SPRL

Novel research models for Alzheimer’s disease and Tauopathies.

Mr. Bart Roucourt

reMYND

The benefits of highly purified gelatins and collagens in regenerative medicine applications: Introducing X-Pure®

Dr. Elke De Clerck

Rousselot

Oct.11(Fri.)      15  :  00  ~  17  :  00

F205-206
【S-24】 Foundation for Biomedical Research and Innovation at Kobe
Pre-Registration required Simultaneous interpretation

 

Coordinator

Mr. Ryuji Hiramatsu

Executive Coordinator
Center for Cluster Development and Coordination
Foundation for Biomedical Research and Innovation at Kobe

Mr. Takeyuki Sato

Director Center for Cluster Development and Coordination
Foundation for Biomedical Research and Innovation at Kobe

In Japanese

Mr. Hisato Doi

President, Representative Director
Evec, Inc.

In Japanese

Mr. Shunichi Takahashi

Head of Open Innovation Center Japan
Open Innovation Center Japan
Bayer Yakuhin, Ltd.

In Japanese

Mr. Kazuhiko Yamamoto

Professor
Graduate School of Science,Technology and Innovation
Kobe University

In Japanese

Mr. Takafumi Yamamoto

CEO& President
TODAI TLO,Ltd.

In Japanese

Mr. Masafumi Mieno

Director
Kobe Biomedical Innovation Cluster Department Biomedical Innovation cluster and Business Promotion Headquarters
KOBE CITY

In Japanese

Mr.

海外から招聘予定

In Japanese